Drug Trial Radar · NCT07911683
Study Evaluating the Efficacy and Safety of BGB-B2033 in Participants With Advanced Hepatocellular Carcinoma
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Nov 30, 2026
Primary completion
Mar 31, 2028
Study completion Sep 30, 2029
Sponsor
- Lead sponsor
- BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
- Sponsor type
- Industry
- First posted
- Nov 3, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of BGB-B2033 monotherapy in adults with hepatocellular carcinoma who have previously been treated with anti-programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) therapies.
Conditions
- Hepatocellular Cancer
- Liver Cancer
- Hepatocellular Carcinoma
Interventions
BGB-B2033Drug
Administered intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response Assessment (ORR) by Independent Review Committee AssessmentTime frame: Up to approximately 15 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.